Dose-Escalation Study of [177Lu]Lu-DOTA-TATE with Standard Care in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma.

The primary objective of this study is to determine the optimal dose of **[177Lu]Lu-DOTA-TATE** in patients with newly diagnosed **glioblastoma** when used in combination with standard of care treatments, as well as in patients with recurrent glioblastoma when used as a single agent. This is clinically relevant as it aims to enhance therapeutic efficacy and improve patient outcomes in a condition known for its aggressive nature and poor prognosis.

The clinical trial involves a total of **21 participants** diagnosed with **glioblastoma**, a highly aggressive form of brain cancer. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The selection process for the trial population is not specified, and no additional demographic or health-related information is available.

The clinical trial is designed to evaluate the efficacy and safety of **[177Lu]Lu-DOTA-TATE** in patients with newly diagnosed and recurrent **glioblastoma**. This study is a Phase 3, randomized, double-blind, controlled trial. The trial is expected to commence recruitment on May 10, 2022, and is estimated to conclude by July 28, 2026. Participants will be randomly assigned to receive either the investigational treatment or a control, with neither the participants nor the investigators aware of the group assignments, ensuring the double-blind nature of the study.

The trial will include several key study visits. Initially, a screening visit will be conducted to assess eligibility based on predefined inclusion and exclusion criteria. Following successful screening, participants will undergo baseline assessments before randomization. Throughout the trial, regular follow-up visits will be scheduled to monitor the participants' health, assess treatment efficacy, and record any adverse events. These visits will occur at predetermined intervals, as outlined in the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the treatment's long-term effects.

Participant involvement is expected to last until the end of the study, unless early termination is warranted. Conditions that may lead to early withdrawal include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The study aims to provide valuable insights into the potential benefits and risks associated with the use of **[177Lu]Lu-DOTA-TATE** in treating **glioblastoma**, contributing to the advancement of therapeutic options for this challenging condition.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments used in this clinical trial can be provided based on the available data.

The clinical trial is in Phase 3 and is scheduled to have an estimated recruitment start date of May 10, 2022, with an estimated end date of July 28, 2026. The efficacy of the intervention will be assessed through various parameters, although specific endpoints and methods for measuring efficacy are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the intervention's impact on the disease, with assessments likely occurring at predetermined intervals throughout the trial duration. The trial's design will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.